Rocket Pharmaceuticals, based in Cranbury, New Jersey, develops gene therapies for rare pediatric diseases and employs 268 people. The company targets conditions like Fanconi Anemia and Leukocyte Adhesion Deficiency-I.
Aaron Ondrey sold 7,489 shares of RCKT on 4 April at $5.29 per share, worth a total of $40K. They now own 129,650 RCKT shares, or a 5% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
